Victory Capital Management Inc. reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 25.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 752,531 shares of the life sciences company’s stock after selling 260,530 shares during the period. Victory Capital Management Inc. owned 0.96% of Integra LifeSciences Holdings Corporation worth $37,988,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. LS Investment Advisors LLC increased its holdings in shares of Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after purchasing an additional 111 shares during the last quarter. Pinebridge Investments L.P. grew its stake in Integra LifeSciences Holdings Corporation by 2.2% during the second quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock worth $435,000 after buying an additional 174 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 3.6% in the second quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock worth $295,000 after acquiring an additional 187 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 8.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 218 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 1.2% in the second quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock worth $1,341,000 after acquiring an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 84.10% of the company’s stock.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill acquired 10,768 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the transaction, the director now directly owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 21.50% of the company’s stock.

IART has been the subject of a number of research reports. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $57.00 target price for the company in a report on Tuesday, October 3rd. Barclays PLC reissued an “equal weight” rating and issued a $53.00 target price (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, September 12th. TheStreet lowered shares of Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a report on Thursday, October 26th. Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, September 10th. Finally, BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $53.64.

TRADEMARK VIOLATION WARNING: “Victory Capital Management Inc. Decreases Holdings in Integra LifeSciences Holdings Corporation (IART)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/08/victory-capital-management-inc-decreases-holdings-in-integra-lifesciences-holdings-corporation-iart.html.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at $47.56 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42. The firm has a market capitalization of $3,744.94, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.09 and a beta of 0.64.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The business had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. Integra LifeSciences Holdings Corporation’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.93 EPS. equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.